Fairvalue-Calculator Fairvalue-Calculator
EN DE

Beijing Tong Ren Tang Chinese Medicine Company (BJTRF) Fair Value & Analysis

Healthcare · US · Market cap $543M

Price$0.6484
Fair Value$1.27
Upside+95.9%
Quality89/100
Evidence: Medium Range $0.9500 – $1.59

Analysis

Beijing Tong Ren Tang Chinese Medicine Company (BJTRF) currently trades at $0.6484, while our model-based Fair Value estimate is $1.27 — implying the stock looks roughly 95.9% undervalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine products to wholesalers and individuals. It operates through Hong Kong, Mainland China, and Overseas segments. The company also offers Chinese medical consultation and treatment services. It markets its products under the Tong Ren Tang brand name. It also operates retail outlets in Hong Kong and in other countries and regions in Asia, the Oceania, North America, and Europe. The company was founded in 1669 and is based in Wan Chai, Hong Kong.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.